




Memorial Sloan Kettering  
Cancer Center

# Aspirin improves liver function and survival after TAE of HCC

**F. Edward Boas, MD PhD**  
**Memorial Sloan Kettering Cancer Center**  
**2018-03-21**  
**[boasf@mskcc.org](mailto:boasf@mskcc.org)**



# Disclosures

## **Financial disclosures**

Ed Boas is a co-founder of Claripacs, LLC. He received research supplies from Bayer (sorafenib). He is an investor in Labdoor, Qventus, CloudMedx, and Notable Labs. He is the inventor and assignee of US patent 8233586.

**Off-label use of medications will be discussed.**



# Adjuvants for locoregional therapy

## Problems with current therapy:

- High rate of recurrence after TACE / TAE.
- On average, only 65% of the tumor is necrotic after TACE of HCC smaller than 5 cm.
- Only 43% of individual lesions showed complete necrosis on histology.

Reference: Golfieri R, et al (2011). *Hepatology* 53: 1580-9.



# Adjuvants for locoregional therapy

## Escape mechanisms that allow tumor cells to survive TACE / TAE:

- Immune tolerance to necrotic tumor
- Ischemia-induced angiogenesis
- Increased anaerobic respiration

Possible solution:

**Several FDA-approved medications block these escape mechanisms.**




# Goal: Find new adjuvant medications

- Determine if outpatient medications taken at the time of liver tumor embolization or ablation affect survival.
- Examine prescription and non-prescription medications, taken for reasons unrelated to the primary cancer diagnosis.



# Treatment groups





# Medications that might improve locoregional therapy

**543** medications taken by patients at time of locoregional therapy

literature search for medications with effect on cancer pathways, ischemia, glucose metabolism, blood flow, angiogenesis, immune response, radiation damage, or heat damage

**29** medications and medication classes





# Examples of medication classes

## Immunomodulatory

- aspirin (116 patients)
- other NSAIDs (106 patients)
- corticosteroids (68 patients)
- other immunosuppressants (20)
- G-CSF (21 patients)
- antiviral for hepatitis B or C (26)

## Glucose metabolism

- insulin (59 patients)
- metformin (52 patients)
- other oral anti-diabetic agents (55)

## Blood flow

- beta blocker (156 patients)
- calcium channel blocker (108)
- ACE inhibitor / ARB (144 patients)
- diuretic (138 patients)

## Radioprotective

- anticoagulant (80 patients)
- NSAID
- corticosteroid (68 patients)
- ursodiol (43 patients)
- vitamin C (33 patients)



# Methods

## Treatment groups

29 medications and  
medication classes

statin  
beta blocker  
CCB  
ACE inhibitor / ARB  
diuretic  
anticoagulant  
anti-platelet  
aspirin  
NSAID (excluding aspirin)  
corticosteroids  
non-corticosteroid immunosuppressant  
G-CSF  
antiviral (anti-hepatitis B/C)  
antiviral (not anti-hepatitis B/C)  
any antiviral  
any antibiotic  
metformin  
non-metformin oral antidiabetic agents  
insulin  
PPI  
gabapentin  
ursodiol  
levothyroxine  
iron  
omega-3 polyunsaturated fatty acids  
folic acid  
cyanocobalamin  
vitamin C  
vitamin D

HCC TAE

Colorectal ablation

Colorectal Y90

NET TAE

For patients taking versus not taking each medication,  
calculate:

- Kaplan Meier curves
- Patient characteristics: AJCC stage, Child Pugh score, comorbidities, ECOG status




## Results: Medications that improve survival after locoregional therapy

HCC TAE	Colorectal ablation	Colorectal Y90	NET TAE
<b>Beta blocker</b>	Beta blocker	(none)	(none)
<b>Aspirin</b>			
Other NSAIDs			
Antiviral (hep B/C)			
PPI			

**Bold medications** remain statistically significant after Bonferroni correction for multiple comparisons ( $p < 0.0017$ ).



# Results: Survival after TAE of HCC



$n = 304$  patients  
 $p = 0.0008$

Number at risk

TAE:	262	168	108	56	29	10	2
TAE + aspirin:	42	23	19	10	7	4	0



## Results: Confounding variables

For patients taking versus not taking aspirin or beta blockers at the time of TAE, there was **no difference in:**

- AJCC stage
- Child Pugh score
- underlying liver disease
- ECOG performance status
- Charlson comorbidity index
- prior sorafenib
- prior liver resection
- selectivity of the embolization



# Aspirin and cancer

- Chronic inflammation plays a key role in cancer development, and this can be blocked by NSAIDS (Weinberg 2014).
- Large randomized trials have shown that aspirin reduces death from colorectal cancer, pancreatic cancer, and other adenocarcinomas (Rothwell 2011).

## References:

- Weinberg RA. (2014) *The Biology of Cancer*. 2nd ed.
- Rothwell PM et al. (2011) *Lancet*. 377(9759): 31-41.



# Aspirin mechanisms

- **Anti-inflammatory:** Aspirin reduces death from chronic liver disease, and reduces development of new HCC.
- **Anti-angiogenic:** Aspirin inhibits hypoxia-induced angiogenesis.
- **Anti-glycolytic:** Aspirin inhibits phosphofructokinase, decreases glucose consumption by tumor cells, and decreases viability of tumor cells.



# Aspirin mechanisms


HCC patients treated with TAE:

	Aspirin ( <i>n</i> =42)	No aspirin ( <i>n</i> =262)	<i>p</i> value
Initial response (CR or PR)	88%	90%	0.6
Median time to progression	6.2 mo	5.2 mo	0.4
Initial site of progression (treated lesion / other liver lesion / extrahepatic lesion)	53% / 40% / 8%	48% / 42% / 11%	0.8
Progression at time of death	88%	89%	1





# Aspirin and liver function



n.s.  $p > 0.05$

\*  $p \leq 0.05$

\*\*  $p \leq 0.01$

\*\*\*  $p \leq 0.001$



# Aspirin and liver function

- Retrospective and animal studies show decreased liver fibrosis in patients / animals taking aspirin.

## References

- Jiang ZG, et al. (2016) *Aliment Pharmacol Ther.* 43: 734-43.
- Sitia G, et al. (2012) *PNAS.* 109: E2165-72.



# Conclusion

- Aspirin and other NSAIDs were associated with improved survival when taken at the time of embolization for HCC.
- Aspirin was not associated with survival differences after locoregional therapy for NET or colorectal liver metastases.
- Aspirin might be hepatoprotective.



# Clinical bottom line

- Consider starting HCC patients on aspirin 81 mg daily before TAE or TACE. (Use caution if history of bleeding or peptic ulcers)
- Baby aspirin does not need to be held before arterial access.
- Beta blockers should be used as first line therapy for peri-procedural hypertension.



# Acknowledgements

## Citations:

- Boas FE, Ziv E, Yarmohammadi H, Brown KT, Erinjeri JP, Sofocleous CT, Harding JJ, Solomon SB. (2017) “Adjuvant medications that improve survival after locoregional therapy.” *Journal of Vascular and Interventional Radiology*. 28: 971-7.
- Boas FE, Brown KT, Ziv E, Yarmohammadi H, Sofocleous CT, Erinjeri JP, Harding JJ, Solomon SB. (2018) “Aspirin is associated with improved liver function after embolization of hepatocellular carcinoma.” Submitted to *Hepatology Research*.

